Albumin nano-encapsulation of caffeic acid phenethyl ester and piceatannol potentiated its ability to modulate HIF and NFkB pathways improving their therapeutic outcome in experimental colitis.

Research output: Contribution to journalArticle

Abstract

Hypoxia inducible factor and nuclear factor kappa beta pathways have been proposed as therapeutic targets for several inflammatory diseases. Caffeic acid phenethyl ester (CAPE) and piceatannol (PIC), are natural anti-inflammatory compounds however, poor
bioavailability and limited understanding of biomolecular mechanistic limits its clinical use. The aims of this study are to enhance bioavailability and investigate their impact on nuclear p65 and HIF-1α for the first time in experimental colitis.
Dextran sulphate sodium was used to induce colitis in mice and effect of either free CAPE/ PIC or CAPE/PIC loaded albumin nanoparticles treatment was observed on disease development and levels of cellular p65 and HIF-1α.
Our results indicate that albumin nano-encapsulation of CAPE / PIC not only enhances its anti-inflammatory potential but also potentiates its ability to effectively modulate
inflammation related biomolecular pathways. Hence, combining nanotechnology with
natural compounds could result in development of new therapeutic options for IBD.
LanguageEnglish
JournalDrug Delivery and Translational Research
Early online date14 Nov 2018
Publication statusE-pub ahead of print - 14 Nov 2018

Fingerprint

Colitis
Encapsulation
Albumins
Esters
Acids
Anti-Inflammatory Agents
Dextran Sulfate
Nanotechnology
Sodium sulfate
Dextran
Therapeutics
Nanoparticles
Biological Availability
caffeic acid phenethyl ester
3,3',4,5'-tetrahydroxystilbene

Keywords

  • nanoparticles
  • inflammation
  • colitis
  • hypoxia
  • nuclear factor kappa beta
  • albumin

Cite this

@article{a0cb12d7479f4de386488a7feac3a8ae,
title = "Albumin nano-encapsulation of caffeic acid phenethyl ester and piceatannol potentiated its ability to modulate HIF and NFkB pathways improving their therapeutic outcome in experimental colitis.",
abstract = "Hypoxia inducible factor and nuclear factor kappa beta pathways have been proposed as therapeutic targets for several inflammatory diseases. Caffeic acid phenethyl ester (CAPE) and piceatannol (PIC), are natural anti-inflammatory compounds however, poorbioavailability and limited understanding of biomolecular mechanistic limits its clinical use. The aims of this study are to enhance bioavailability and investigate their impact on nuclear p65 and HIF-1α for the first time in experimental colitis.Dextran sulphate sodium was used to induce colitis in mice and effect of either free CAPE/ PIC or CAPE/PIC loaded albumin nanoparticles treatment was observed on disease development and levels of cellular p65 and HIF-1α.Our results indicate that albumin nano-encapsulation of CAPE / PIC not only enhances its anti-inflammatory potential but also potentiates its ability to effectively modulateinflammation related biomolecular pathways. Hence, combining nanotechnology withnatural compounds could result in development of new therapeutic options for IBD.",
keywords = "nanoparticles , inflammation , colitis, hypoxia, nuclear factor kappa beta, albumin",
author = "Tambuwala, {Murtaza M} and Khan, {Mohammed Naeem} and Paul Thompson and McCarron, {P. A.}",
year = "2018",
month = "11",
day = "14",
language = "English",
journal = "Drug Delivery and Translational Research",
issn = "2190-393X",

}

TY - JOUR

T1 - Albumin nano-encapsulation of caffeic acid phenethyl ester and piceatannol potentiated its ability to modulate HIF and NFkB pathways improving their therapeutic outcome in experimental colitis.

AU - Tambuwala, Murtaza M

AU - Khan, Mohammed Naeem

AU - Thompson, Paul

AU - McCarron, P. A.

PY - 2018/11/14

Y1 - 2018/11/14

N2 - Hypoxia inducible factor and nuclear factor kappa beta pathways have been proposed as therapeutic targets for several inflammatory diseases. Caffeic acid phenethyl ester (CAPE) and piceatannol (PIC), are natural anti-inflammatory compounds however, poorbioavailability and limited understanding of biomolecular mechanistic limits its clinical use. The aims of this study are to enhance bioavailability and investigate their impact on nuclear p65 and HIF-1α for the first time in experimental colitis.Dextran sulphate sodium was used to induce colitis in mice and effect of either free CAPE/ PIC or CAPE/PIC loaded albumin nanoparticles treatment was observed on disease development and levels of cellular p65 and HIF-1α.Our results indicate that albumin nano-encapsulation of CAPE / PIC not only enhances its anti-inflammatory potential but also potentiates its ability to effectively modulateinflammation related biomolecular pathways. Hence, combining nanotechnology withnatural compounds could result in development of new therapeutic options for IBD.

AB - Hypoxia inducible factor and nuclear factor kappa beta pathways have been proposed as therapeutic targets for several inflammatory diseases. Caffeic acid phenethyl ester (CAPE) and piceatannol (PIC), are natural anti-inflammatory compounds however, poorbioavailability and limited understanding of biomolecular mechanistic limits its clinical use. The aims of this study are to enhance bioavailability and investigate their impact on nuclear p65 and HIF-1α for the first time in experimental colitis.Dextran sulphate sodium was used to induce colitis in mice and effect of either free CAPE/ PIC or CAPE/PIC loaded albumin nanoparticles treatment was observed on disease development and levels of cellular p65 and HIF-1α.Our results indicate that albumin nano-encapsulation of CAPE / PIC not only enhances its anti-inflammatory potential but also potentiates its ability to effectively modulateinflammation related biomolecular pathways. Hence, combining nanotechnology withnatural compounds could result in development of new therapeutic options for IBD.

KW - nanoparticles

KW - inflammation

KW - colitis

KW - hypoxia

KW - nuclear factor kappa beta

KW - albumin

UR - https://link.springer.com/article/10.1007/s13346-018-00597-9

M3 - Article

JO - Drug Delivery and Translational Research

T2 - Drug Delivery and Translational Research

JF - Drug Delivery and Translational Research

SN - 2190-393X

ER -